Mohty Mohamad, Gaugler Béatrice, Calmels Boris, Blaise Didier, Vey Norbert, Chabannon Christian, Olive Daniel
Laboratoire d'immunologie des tumeurs, Institut Paoli-Calmettes, Centre régional de lutte contre le cancer Provence-Alpes-Côte d'Azur, 232, boulevard de Sainte-Marguerite, 13273 Marseille, France.
Bull Cancer. 2003 Aug-Sep;90(8-9):751-7.
Prognosis of acute myeloblastic leukemias (AML) remains with relapse, at a time when progress in chemotherapy regimens have increased the rate of complete remission, and improved biological tools have helped in defining diagnostic and prognostic criteria for this heterogeneous group of diseases. Allogeneic stem cell transplantation offers an example of a situation in which various immune effectors can contribute to the eradication of residual leukemic cells. However, use of allogeneic transplantation is restricted to a minority of patients. Thus, the development of immunotherapy strategies that could be used for all patients, appears highly desirable. Progress in fundamental immunology, and a better understanding of the role of the immune system in the physiopathology of leukemias now open new avenues to design innovative therapies. We here review recently published observations in this field, and propose new vaccine programs that use autologous AML blasts differentiated into dendritic cells.
急性髓细胞白血病（AML）的预后仍然与复发相关，尽管化疗方案的进展提高了完全缓解率，并且改进的生物学工具有助于确定这类异质性疾病的诊断和预后标准。异基因干细胞移植就是一个例子，其中各种免疫效应器可有助于清除残留的白血病细胞。然而，异基因移植的使用仅限于少数患者。因此，开发可用于所有患者的免疫治疗策略显得非常必要。基础免疫学的进展以及对免疫系统在白血病生理病理学中作用的更好理解，现在为设计创新疗法开辟了新途径。我们在此回顾该领域最近发表的观察结果，并提出使用分化为树突状细胞的自体AML母细胞的新疫苗方案。
